Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now displays an administrative notice about funding status and the NIH Clinical Center's operations, along with a new revision tag (Revision: v3.4.1). These changes do not modify trial data, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-03T23:49:49.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now displays a Show glossary option and new metadata fields (Last Update Submitted that Met QC Criteria and Last Update Posted) along with No FEAR Act Data and Revision: v3.4.0, replacing the previous labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).
    Difference
    0.3%
    Check dated 2026-01-27T21:32:00.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    New data points were added to the study record, including several key dates (2026-01-02, 2023-08-04, 2027-09-01, 2025-12-30) and a Last Update Posted (Estimated) label. Older sponsor details and past update entries (e.g., Nancy Chan, MD, Big Ten Cancer Research Consortium) were removed.
    Difference
    0.8%
    Check dated 2026-01-06T02:04:22.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    - Added a new Locations section listing Michigan, Nebraska, New Jersey, New York, and Wisconsin. Removed the separate Michigan, Nebraska, New Jersey, New York, and Wisconsin location blocks.
    Difference
    0.7%
    Check dated 2025-12-22T20:39:48.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.3.1 to v3.3.2; this appears to be a minor backend or formatting change with no edits to study details, eligibility, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-08T18:46:47.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.1 on the page.
    Difference
    0.1%
    Check dated 2025-11-24T14:48:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.